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Abstract
Background: Due to its potential beneficial effects, intra- and postoperative application of intravenous lidocaine
has become increasingly accepted over the last couple of years, e.g. in patients undergoing laparoscopic surgical
procedures. Based on its beneficial properties, lidocaine was introduced to the standard of care for all pediatric
laparoscopic procedures in our institution in mid-2016. In contrast to adult care, scarce data is available regarding
the use of perioperative intravenous lidocaine administration in children undergoing laparoscopic procedures, such
as an appendectomy.
Methods: Retrospective analysis of all pediatric patients undergoing laparoscopic appendectomy at the University
Children’s Hospital Zurich in 2016. Perioperative data, as recorded in the electronic patient data management
system, were evaluated for any signs of systemic lidocaine toxicity (neurological and cardiovascular), behavioral
deterioration, as well as for hemodynamic instability. Additionally, the incidence of postoperative nausea and
vomiting, administration of pain rescue medication, time to hospital discharge and to first bowel movement, as
well as any postoperative complications were recorded. Starting on 01/07/2016, all patients undergoing
laparoscopic surgery received intravenous lidocaine (1.5 mg/kg body weight (BW) bolus after induction of
anesthesia followed by continuous infusion of 1.5 mg/kgBW/h). These patients were then compared to children
without lidocaine administration who had undergone laparoscopic appendectomy between 01/01/2016 and 30/06/
2016.
Results: Data of 116 patients was analyzed. Of these, 60 patients received lidocaine. No signs of systemic toxicity,
neurologic impairment or circulatory disturbances were noted in any of these patients. A (non-significant)
difference in the incidence of emergence delirium was observed (0 cases in the lidocaine group vs. 4 cases in the
control group, p = 0.05).
Conclusion: This retrospective analysis did not reveal any adverse effects in pediatric patients receiving intravenous
lidocaine for laparoscopic appendectomy under general anesthesia. However, further trials investigating beneficial
effects as well as pharmacokinetic properties of intravenous lidocaine in children are required.
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Background
Lidocaine has been in clinical use for loco-regional
anesthesia as well as for the treatment of arrhythmias
for several decades [1]. Over the last couple of years, the
intravenous application of the drug has also gained more
and more attention, e.g. as part of a multimodal therapy
concept for perioperative pain [2, 3], although it is still
considered to be an off-label use [4].
In adults, several clinical trials have examined potential
beneficial effects of perioperative intravenous lidocaine
use due to its anti-inflammatory characteristics [5–8], e.g.
in patients undergoing laparoscopic procedures [9–13]. A
recent Cochrane analysis assessing 45 trials with 2802
mixed surgical patients found low to moderate evidence
that intravenous lidocaine might be able to reduce early
postoperative pain scores and PONV, as well as some lim-
ited evidence for a beneficial effect on other postoperative
parameters, such as post-operative opioid requirements,
the length of hospital stay or the time to first bowel move-
ment [14]. However, to our knowledge, no data is available
regarding the safety of continuous perioperative lidocaine
infusion in children.
Based on its potential beneficial effects regarding post-
operative pain control or postoperative nausea and
vomiting (PONV), we introduced the additive periopera-
tive administration of intravenous lidocaine to our
standard anesthesia regimen for all laparoscopic proce-
dures on July 1st, 2016.
The primary goal of this study was to retrospectively
evaluate adverse effects of the intra- and post-operative
application of intravenous lidocaine in patients undergo-
ing laparoscopic appendectomy compared to a historical
cohort prior to the introduction of lidocaine. Addition-
ally, the study aimed at evaluating any potential benefi-
cial effects of intravenous lidocaine, such as
postoperative opioid requirements, PONV, time to hos-
pital discharge and bowel movement as well as any post-
operative complications.
Methods
With approval of the local ethics committee (Kantonale
Ethikkommission, Zurich, Switzerland; study protocol
BASEC number: 2016–00188) our anesthesia electronic
patient data management system was screened for pa-
tients undergoing laparoscopic appendectomy in 2016.
To minimize possible confounders, we excluded all pa-
tients who had not received dexamethasone for any rea-
son (Fig. 1).
Data collection
Data were collected from premedication reports and the
perioperative patient data management system (MetaVi-
sion, Version 5.46.44, iMDsoft, Duesseldorf, Germany)
as well as from the patient’s electronic medical records.
The primary endpoint was the incidence of any periopera-
tive neurologic (perioral tingling, numbness, seizures)
symptoms. Circulatory symptoms (cardio-respiratory col-
lapse or arrest; severe, prolonged or refractory
hypotension) as well as apparent behavioral deterioration
in the postoperative period such as emergence delirium
(ED) documented by PACU or ward staff, were also noted.
The assessment of ED is based on clinical criteria of the
Pediatric Anesthesia Emergence Delirium (PAED) scale
[15]. Besides epidemiological and perioperative data, the
duration of continuous lidocaine infusion and the total
amount of lidocaine administered were recorded. Add-
itionally, the need for any rescue medication against pain,
PONV, the time to first postoperative bowel movement
and to hospital discharge after surgery, as well as the inci-
dence of post-operative complications (as classified by the
Dindo-Clavien score [16]) were evaluated.
Management of general anesthesia
The standard premedication drug for children above the
age of 6 months is midazolam (0.5 mg/kg body weight
(BW), with a maximum of 10 mg orally or rectally) given
20–45 min (depending on the route of application) prior to
the transfer to the operating theater. For induction of gen-
eral anesthesia, opioids (either alfentanil 10–15 mcg/kgBW)
or fentanyl (1–3 mcg/kgBW), and propofol (3–5 mg/kgBW)
were used, followed by atracurium (1 mg/kgBW) for muscle
paralysis. Controlled rapid sequence induction and intub-
ation was performed with gentle mask ventilation prior to
endotracheal intubation with a cuffed tube. Anesthesia was
maintained either with sevoflurane or a continuous infusion
of propofol. Intraoperative analgesia was provided via bolus
Fig. 1 Patient flow chart
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administration of either alfentanil of fentanyl. Dexametha-
sone (0.2 mg/kg, max. 8 mg in total), paracetamol and
metamizole (15 mg/kgBW each) were administered during
anesthesia for initial postoperative pain relief.
All patients received crystalloid fluids (Ringer’s acetate
glucose 1%, Bichsel, Switzerland) for maintenance fluid in-
take. Additional fluids were administered in case of noted
hypotension, using a bolus of crystalloids (Ringer-acetate
Fresenius i.v., Fresenius Kabi, Switzerland) or colloid fluid
solutions (Physiogel® balanced, B. Braun Medical AG,
Switzerland). The choice of fluid for the bolus was left to
the discretion of the anesthesiologist in charge.
Administration of lidocaine 1% (without preservatives,
Hospital Pharmacy, University Children’s Hospital
Zurich, Switzerland) was initiated shortly after tracheal
intubation in hemodynamically stable patients starting
with an intravenous bolus of 1.5 mg/kgBW followed by
a continuous infusion at a rate of 1.5 mg/kgBW/h. The
latter was continued until the patient was transferred to
the ward postoperatively (either directly from the operat-
ing theater or from the post-anesthesia care unit
(PACU)). Contraindications for the application of lido-
caine were a known allergy against any local anesthetic
as well as hemodynamic instability.
For wound infiltration, 25% of the maximum bupiva-
caine dose, i.e. 0.125 ml/kgBW of bupivacaine 0.5%
(carbostesin 0.5%, Aspen Pharma, Switzerland) were
allowed and were usually administered by the surgeon at
the end of surgery.
Statistical analysis
Categorical data are expressed as the number of patients
together with their corresponding percentage of their
total group (control = no lidocaine versus lidocaine). Dif-
ferences between the proportions of qualitative data
were assessed with χ2 or Fisher’s Exact test where appro-
priate. Quantitative data were assessed for normal distri-
bution using the Shapiro-Wilk test. Normally distributed
data are expressed as mean (SD) and Student’s t-test was
used for inter-group comparison. Non-parametric data
are reported as median (interquartile range (IQR)) and
were compared using a Mann-Whitney U test. Spearman
correlation analysis was performed for the evaluation of
the relationship between specific factors. A p-value < 0.05
was considered to be statistically significant. All analyses
were conducted using the SPSS software for Mac (Version
23, IBM Corp, Armonk, NY, USA).
Results
A total of 8477 patients were anesthetized in our institu-
tion in 2016. Of these, 198 patients received anesthesia
for laparoscopic procedures and 141 underwent laparo-
scopic appendectomy. Finally, a total of 116 patients
who had received anesthesia for laparoscopic appendec-
tomy and received dexamethasone underwent further
analysis (for flowchart see Fig. 1).
Patient characteristics are summarized in Table 1. Pa-
tients in the lidocaine group received a mean total of 4.88
(SD 2.76) mg/kgBW lidocaine over 118.2 (57.5) minutes
(Table 2). In patients who had received fentanyl only after
the induction of anaesthesia, a non-significant difference
in the amount of the applied fentanyl could be observed,
with patients in the lidocaine group tending to receive less
(median of 4.6 vs. 3.7 mcg/kgBW, p = 0.12, all Table 2).
No difference could be detected in the mean amount
of crystalloids applied, but the number of patients re-
ceiving colloids or ephedrine was higher in the lidocaine
group, although these differences did not reach statistical
significance (p = 0.115 for colloids, p = 0.111 for ephe-
drine). A Spearman’s correlation analysis evaluating the
relationship between a perforated appendix and the in-
traoperative use of colloids or ephedrine revealed a
(weak) correlation for colloids (correlation coefficient
0.25, p = 0.007), whereas there was no correlation be-
tween the use of ephedrine and a perforated appendix
(correlation coefficient − 0.13, p = 0.89). The higher
number of patients with a perforated appendix in the
lidocaine group (12 vs. 20 patients, p = 0.152, Table 2),
Table 1 Baseline characteristics of patients
Variable Control (n = 56) Lidocaine (n = 60) p-value
Age [yrs]
Mean (SD) 10.46 (3.63) 10.19 (3.76) 0.69 a
Gender
Female/Male (%) 33 / 23 (58.9 / 41.1) 30 / 30 (50 / 50) 0.335 b
Weight [kg]
Median (IQR) 38.4 (26.5) 35.9 (22.8) 0.3 c
ASA score [number (%)]
I / II / III 39 (69.6) / 15 (26.8) / 2 (3.6) 31 (51.7) / 26 (43.3) / 3 (5.0) 0.140 b
Premedication [number (%)] 50 (89.3) 54 (90.0) 0.9 b
a = Student's t-test, b = Chi-square, c = Mann-Whitney U
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might therefore be a possible explanation for the higher
rate of colloid administration in the lidocaine group.
The prescription of postoperative analgesics differed
significantly between the two groups, with the lidocaine
group requiring less non-opioid analgesics than the con-
trol group (p = 0.005, Table 3). However, no difference in
postoperative opioid requirements could be detected
(Table 3).
No neurological disturbances (seizures, numbness, tin-
gling, paresthesias) were noted in any of the patients re-
ceiving lidocaine. Instead, there was a trend towards a
lower incidence of ED in the lidocaine group (4 vs. 0 pa-
tients, p = 0.05, Table 4).
None of the patients suffered from cardio-respiratory
collapse or arrest, severe, prolonged or refractory
hypotension or arrhythmias, especially bradycardia.
A subgroup analysis of all patients with a perforated ap-
pendix revealed similar results as observed for the whole
study population (Table 5). The median time to the first
postoperative bowel movement seemed to be lower in the
lidocaine group, although this difference was not statisti-
cally significant (median of 59 vs. 39 h, p = 0.27).
Discussion
This retrospective study analyzed perioperative factors
associated with the systemic use of lidocaine in pediatric
Table 2 Perioperative characteristics of patients
Variable Control (n = 56) Lidocaine (n = 60) p-value
Duration of surgery [min]
Mean (SD) 79.98 (30.92) 78.50 (34.92) 0.810 a
Amount of lidocaine administered [mg/kg BW]
Mean (SD) n/a 4.88 (2.76)
Duration of lidocaine administration [min]
Mean (SD) n/a 118.2 (57.5)
Type of anesthesia [number (%)] 0.639 d
Inhalation 43 43
TIVA 10 15
Balanced 3 2
Opioids at induction of anesthesia [number (%)] 55 (98.2) 58 (96.7) 1 d
Alfentanil 45 (81.8) 53 (91.4) 0.203 d
Fentanyl 9 (16.4) 5 (8.6)
Alfentanil + Fentanyl 1 (1.8) 0 (0)
Opioids after induction [number (%)] 56 (100.0) 60 (98.3)
Alfentanil only 1 (1.8) 0 (0)
Fentanyl only 40 (71.4) 49 (81.7)
Fentanyl intraoperative [mcg/kg BW]
Median (IQR) 4.63 (2.68) 3.7 (1.95) 0.123 c
Alfentanil + Fentanyl 12 (21.4) 3 (5.0)
Fentanyl + Remifentanil 3 (5.4) 6 (10.0)
Fentanyl + Morphine 0 (0) 1 (1.7)
Perforated appendix [number (%)] 12 (21.4) 20 (33.3) 0.152 b
Crystalloids [ml/kg BW]
Mean (SD) 30.12 (23.11) 27.92 (14.55) 0.539 a
Colloids [number (%)]
Total 1 (1.8) 6 (10.0) 0.115 d
Perforated / Non-perforated 1 / 0 4 / 2 1 d
Ephedrine administration [number (%)]
Total 6 (10.7) 13 (21.7) 0.111 b
Perforated / Non-perforated [number] 1 / 5 9 / 4 1 d
a = Student's t-test, b = Chi-square, c =Mann-Whitney U, d = Fisher’s Exact; balanced anesthesia = combination of intravenous and volatile anesthetics, SD = standard
deviation, IQR = interquartile range, BW= body weight
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patients. Based on our knowledge, it includes the
highest number of pediatric patients assessed for the
effects of the drug after administering it intra- and
postoperatively. On July 1st, 2016, perioperative ad-
ministration of intravenous lidocaine was added to
our standard of care for all laparoscopic procedures
at the University Children’s Hospital Zurich,
Switzerland. This decision was based on the strong
evidence for potential beneficial effects, for example
regarding postoperative pain control or PONV. As
appendectomy was the most common laparoscopic
procedure in our institution and in order to minimize
possible confounders, only data from patients under-
going this particular surgery were analyzed.
Table 3 Postoperative analgesic requirements in all patients
Variable Control (n = 56) Lidocaine (n = 60) p-value
Postoperative analgesia with non-opioids [number (%)] 0.005*c
Paracetamol only 0 (0) 3 (5)
Paracetamol + Metamizol 52 (92.9) 49 (81.7)
Paracetamol + Ibuprofen 1 (1.8) 8 (13.3)
Paracetamol + Metamizol + Ibuprofen 3 (5.4) 0 (0)
Any opioid in PACU/immediately post-op [number (%)] 23 (41.1) 24 (40) 0.906 a
PCA post-operative [number (%)]
Any 8 (14.3) 13 (21.7) 0.302 a
Nalbuphine 3 (5.4) 11 (18.3)
Morphine 5 (8.9) 2 (3.3)
PCA duration [hrs]
Median (IQR) 54.5 (26) 39 (49) 0.336 b
Any pain rescue medication first 24 h post-op [number (%)] 34 (60.7) 39 (65.0) 0.633 a
a = Chi-square, b = Mann-Whitney U, c = Fisher’s Exact, IQR = interquartile range, significant effects (p<0.05) are marked with “*” and presented in bold and
italic font
Table 4 Postoperative outcome measures of all patients
Variable Control (n = 56) Lidocaine (n = 60) p-value
PONV [number (%)] 17 (30.4) 21 (35.0) 0.594 b
Additional PONV-prophylaxis [number (%)] 0.087 d
None 7 (12.5) 14 (23.3)
Ondansetron 49 (87.5) 44 (73.3)
Ondansetron + Droperidol 0 (0) 2 (3.3)
Emergence delirium [number (%)] 4 (7.1) 0 (0) 0.05 d
Time to first bowel movement post-op [hrs]
Median (IQR) 48 (25) 40 (30) 0.05 c
Post-op complications [number (%)]
Any 6 (10.7) 5 (8.3) 0.757 d
Dindo Score
I 1 (1.8) 2 (3.3)
II 5 (8.9) 2 (3.3)
III 0 (0) 1 (1.7)
IV 0 (0) 0 (0)
Discharge after surgery [days]
Mean (SD) 3.75 (2.77) 4.67 (4.52) 0.19 a
a = Student's t-test, b = Chi-square, c = Mann-Whitney U, d = Fisher’s Exact. Dindo Score of postoperative surgical complications [16]: I = alteration of normal
postoperative course, no surgical, endoscopic or radiologic intervention needed, allowed medications in grade I: antiemetics, antipyretics, analgetics, diuretics,
electrolytes;
II = pharmacological treatments other than allowed in grade I, including blood transfusions and total parenteral nutrition; III = complications requiring surgical,
endoscopic or radiological intervention, IV = life-threatening complication requiring intensive care unit
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The main finding was that neither signs of local
anesthetic systemic toxicity nor circulatory instability or
disturbances were noted in any of the patients
investigated.
Local anesthetic systemic toxicity (LAST) has been
discussed and studied at large in recent years and
guidelines have been implemented for its treatment
[17]. However, most of the previously published ana-
lyses have examined the incidence of LAST after per-
ipheral nerve blocks and not after intravenous use [18]
and only scarce evidence exists regarding safety and po-
tentially beneficial effects of intravenous lidocaine in
children. In a study of 91 patients undergoing proced-
ural sedation no benefit of pre-emptive lidocaine ad-
ministration (0.5 mg/kgBW bolus) on the injection pain
due to propofol could be detected [19]. Two small stud-
ies have examined safety aspects of intravenous lido-
caine for the treatment of chronic pain in adolescents
[20, 21]: Mooney and colleagues reported a small series
of 15 patients aged 12–19 years, who had received a
total of 58 lidocaine infusions with an infusion rate of
up to 60 μg/kg/min (i.e. 3.6 mg/kgBW/h) with no initial
bolus. The most common side effects reported were
“dizziness” and sensations termed as “numbness” or
“tingling”, which occurred in 16 and 10%, respectively.
However, 79% did not experience any side effects at all
[20]. The other recent study retrospectively analyzed 4
patients aged 8–18 years undergoing several treatments
with intravenous lidocaine for opioid-refractory cancer
pain: Here the authors reported an incidence of side ef-
fects such as visual changes or hallucinations, as well as
paresthesias during 35% of the treatments [21]. How-
ever, with a median infusion rate of 30 μg/kg/min (i.e.
1.8 mg/kgBW/h), the rate in these patients was still
higher than in our institution (1.5 mg/kgBW/h). Due to
the fact that it is impossible to detect most of these
symptoms with the patient held under general
anesthesia, the current study might of course fail in de-
tecting them.
The dosage of 1.5 mg/kgBW bolus as used in the
current study has been chosen after it has been reported
as the most common dose used in 64% of trials included
in a recent Cochrane analysis [14]. According to the
same Cochrane analysis, the continuous infusion rate of
1.5 mg/kgBW/h might be rather low compared to other
studies but has still been reported to be effective in
Table 5 Postoperative outcome measures in patients with perforated appendicitis
Variable Control (n = 12) Lidocaine (n = 20) p-value
PONV [number (%)] 4 (33.3) 6 (30.0) 1 b
Emergence delirium [number (%)] 2 (16.7) 0 (0) 0.133 b
Any opioid in PACU/immediately post-op [number (%)] 5 (41.7) 6 (30.0) 0.7 b
PCA post-operative [number (%)]
Any 5 (41.7) 7 (35.0) 0.724 b
Nalbuphine 1 (8.3) 6 (30.0)
Morphine 4 (33.3) 1 (5.0)
PCA duration [hrs]
Median (IQR) 62 (39) 48 (30) 0.43 a
Any pain rescue medication first 24 h post-op [number (%)] 10 (83.3) 12 (60.0) 0.248 b
Post-op complications [number (%)]
Any 5 (41.7) 5 (25.0) 0.438 b
Dindo Score
I 1 (8.3) 2 (10.0)
II 4 (33.3) 2 (10.0)
III 0 (0) 1 (5.0)
IV 0 (0) 0 (0)
Time to first bowel movement post-op [hrs]
Median (IQR) 59 (34) 38.5 (31) 0.27 a
Discharge after surgery [days]
Median (IQR) 7 (6) 6 (4) 0.92 a
a =Mann-Whitney U, b = Fisher’s Exact. Dindo Score of postoperative surgical complications [16]: I = alteration of normal postoperative course, no surgical,
endoscopic or radiologic intervention needed, allowed medications in grade I: antiemetics, antipyretics, analgetics, diuretics, electrolytes; II = pharmacological
treatments other than allowed in grade I, including blood transfusions and total parenteral nutrition; III = complications requiring surgical, endoscopic or
radiological intervention, IV = life-threatening complication requiring intensive care unit
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combination with a reasonable risk of toxicity [14].
However, it might of course be difficult to predict toxic
effects only based on weight adjusted administration
local anesthetics due to their cumulative effects [22].
No neurologic side effects, such as visual disturbances,
tingling or paresthesia, have been observed by the PACU
staff, even in patients fully awake again after emergence
from general anesthesia, while still under continuous
lidocaine infusion or after being transferred to the ward
shortly after the cessation of the lidocaine infusion.
The new and unexpected finding in the current study
was the trend towards a reduction of the incidence of
emergence delirium (ED) in patients receiving lidocaine.
ED is a common event in pediatric anesthesia with an
incidence varying between 10 and 67% [23]. The preva-
lence of ED has risen with the more widespread use of
sevoflurane (and desflurane) [24], however, the patho-
physiologic changes leading to this phenomenon are not
completely understood. In adults, endothelial dysfunc-
tion due to the release of inflammatory cytokines is a
common perioperative event and a crucial factor influ-
encing the incidence of delirium [25, 26]. Amide-local
anesthetics have been demonstrated to be able to pre-
serve endothelial barrier function upon an inflammatory
stimulus [5, 6] and might therefore also potentially be
able to influence pathophysiologic events leading to
neurologic disturbances after surgery.
Postoperative pain might not also be a trigger for ED,
but might it also be difficult to be discriminated from
the latter [27] and it is known that pain is a common
problem after paediatric laparoscopic appendectomy,
with 33% of children suffering from substantial pain on
the day of surgery and still 20% on postoperative day 1
in a recent retrospective study of 186 patients [28]. Pa-
tients in the current study received a well-established,
pre-emptive analgesic regimen, which might also impede
the detection of a possible effect of lidocaine in this set-
ting. However, we could detect a significantly lower pre-
scription rate of non-opioid analgesics in the lidocaine
group, whereas the number of patients requiring any
form of opioid rescue medication did not differ between
the groups.
A suggested reduction of PONV by lidocaine might also
be difficult to reproduce in this specific patient population,
as patients with an acute appendicitis already show signs
of severe inflammation as well as nausea and vomiting pre-
operatively caused by intestinal disturbances [29, 30]. In
addition, all patients in the current study received at least
dexamethasone as an anti-emetic prophylaxis (with 82%
receiving a second drug as well), which might also make it
even more difficult to detect any lidocaine-associated ben-
efits regarding PONV and pain [31].
The time to first bowel movement was reduced in the
lidocaine group by 17% overall and by 33% in patients
with a perforated appendicitis, although the detected dif-
ferences did not reach statistical significance. However,
these findings are in accordance with a recent Cochrane
analysis suggesting a beneficial effect of lidocaine via an
enhanced gastrointestinal recovery in patients undergo-
ing abdominal surgery [14].
There are several limitations of this study, which were
mainly due to its retrospective character. Overall, inter-
pretation of the reported data should be made with cau-
tion, especially due to the fact that this study compares
patients with lidocaine administration to a historic group
of patients without. Additionally, the number of patients
is rather small, which might explain the fact that several
observed differences did not reach statistical signifi-
cance. Additionally, the limited data on postoperative
pain intensity and quality makes it difficult to conclude
a potential beneficial effect of lidocaine on postoperative
analgesia in this specific patient population.
Conclusions
In this retrospective data analysis in a limited number of
pediatric patients undergoing general anesthesia for lap-
aroscopic appendectomy, the perioperative continuous ad-
ministration of intravenous lidocaine did not lead to any
adverse effects. However, beneficial effects should further
be assessed in future randomized controlled clinical trials
in combination with a potentially more detailed analysis
regarding the effects as well as the pharmacokinetic prop-
erties of lidocaine in the pediatric population.
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